Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury

Flor M Fernández-Gordón Sánchez; Elena Gómez-Domínguez; Diana Paredes Ruiz; Yolanda Rodríguez Gil; Ana Martín Algíbez; Inmaculada Fernández Vázquez; Pilar Martínez Montiel

doi:10.17235/reed.2022.8618/2022

Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury

Rev Esp Enferm Dig. 2022 Jun;114(6):356-357. doi: 10.17235/reed.2022.8618/2022.

Authors

Flor M Fernández-Gordón Sánchez¹, Elena Gómez-Domínguez², Diana Paredes Ruiz³, Yolanda Rodríguez Gil⁴, Ana Martín Algíbez², Inmaculada Fernández Vázquez², Pilar Martínez Montiel²

Affiliations

¹ Digestive Diseases, Hospital Universitario 12 de Octubre, España.
² Digestive Diseases, Hospital Universitario 12 de Octubre.
³ Internal Medicine, Hospital Universitario 12 de Octubre.
⁴ Pathology, Hospital Universitario 12 de Octubre.

PMID: 35073724
DOI: 10.17235/reed.2022.8618/2022

Abstract

Pembrolizumab, a programmed cell death receptor (PD-1) inhibitor, have improved the prognosis in several types of cancer. Despite the important clinical benefits, checkpoint inhibition have been associated with inflammatory and immune-related side effects (irAE).

MeSH terms

Antibodies, Monoclonal, Humanized
Colitis* / chemically induced
Colitis* / drug therapy
Humans
Immune System Diseases*
Liver
Programmed Cell Death 1 Receptor
Ustekinumab / adverse effects

Substances

Antibodies, Monoclonal, Humanized
Programmed Cell Death 1 Receptor
pembrolizumab
Ustekinumab